Andrew Witty

Andrew Witty
Born	Andrew Philip Witty 8/22/1964
Birthplace	Nantwich, England
Nationality	British
Occupation	Business executive
Known for	CEO of UnitedHealth Group (2021–2025), CEO of GlaxoSmithKline (2008–2017)
Education	University of Nottingham
Spouse(s)	Caroline Hall
Children	2
Awards	Knight Bachelor (2012), Honorary Citizen of Singapore (2018)

Sir Andrew Philip Witty (born 22 August 1964) is an English business executive who led UnitedHealth Group, America's largest health insurance company, from February 2021 until his abrupt exit in May 2025. Before that, he spent nearly three decades at British pharmaceutical firm GlaxoSmithKline (GSK), working his way up through international operations to become CEO from 2008 to 2017. At GSK, Witty championed expanded access to medicines in developing countries and steered the company through a serious bribery scandal in China. After leaving GSK, he became president of UnitedHealth's Optum division, then took the top job at the parent company. In 2020, he stepped away from Optum temporarily to help the World Health Organization coordinate vaccine development efforts for COVID-19. He was knighted in the 2012 New Year Honours for services to the pharmaceutical industry and the economy, and he served as chancellor of the University of Nottingham from 2013 to 2017. His four-decade career spanned two of the world's largest healthcare organisations, making him one of the most visible figures in global health during the early 21st century.

Early Life

Andrew Philip Witty was born on 22 August 1964 in Nantwich, a market town in Cheshire, England. Public information about his family and childhood is sparse. He attended the University of Nottingham, where he studied economics and graduated in 1985. That university would stay important to him throughout his career, eventually as its chancellor.

Witty joined Glaxo plc in 1985, launching what'd become a 32-year run with the company and its successors. He started during a transformative period. The British pharmaceutical sector was consolidating rapidly, and Glaxo was establishing itself as a global powerhouse.

Education

Economics was his subject at the University of Nottingham, where he earned his degree in 1985. He'd maintain strong ties to the university long afterward. Come 2013, he took on the role of chancellor, a mostly ceremonial position he held until 2017. In that capacity, he presided over graduation ceremonies and acted as an ambassador for the institution.

Career

GlaxoSmithKline (1985–2017)

Witty joined Glaxo plc in 1985 right after graduating from the University of Nottingham. Over the next twenty years, he moved through various roles across the company's international operations. Glaxo underwent major changes during this stretch. It became Glaxo Wellcome in 1995 and then merged with SmithKline Beecham to form GlaxoSmithKline (GSK) in 2000. Witty gained broad exposure to emerging markets, holding management positions across Africa and Asia. His postings included running GSK's South Africa operations and later the Asia-Pacific region, giving him real insight into healthcare access challenges in the developing world. That experience would shape his strategy once he became CEO.

Appointment as CEO

GSK announced in October 2007 that Witty would succeed Jean-Pierre Garnier as chief executive officer, taking over in May 2008. At 43, he was fairly young for the top job at a pharmaceutical giant. Times writers noticed his extensive background managing GSK's global network when they profiled him.

Strategy and Global Health Initiatives

Witty took a different approach when he became CEO in 2008. Most peers in pharma wouldn't have gone the same direction. In February 2009, he announced initiatives to improve how medicines got to developing countries. Prices for GSK drugs in the poorest nations dropped. The company reinvested some profits made in least-developed countries back into healthcare infrastructure there. They also shared research into neglected tropical diseases by putting relevant patents into a pool others could access. Witty told The Guardian that the existing intellectual property system wasn't working for the developing world.

Global health advocates and policymakers took notice. Still, some investment analysts worried the approach would hurt shareholder returns. Investor Neil Woodford, then one of GSK's biggest shareholders, publicly attacked Witty's strategic direction, insisting the company needed stronger financial performance.

China Bribery Scandal

A major bribery scandal hit GSK in China during Witty's time as CEO. Chinese authorities said GSK employees had routed money through travel agencies and similar intermediaries to bribe doctors and hospital officials into prescribing GSK products. The scandal resulted in fines and criminal charges against several GSK staff members in China.

Witty went public with his response. He called the alleged corrupt practices a clear violation of GSK's governance and compliance rules. In an interview with The Independent, he stated that GSK's UK headquarters had no prior knowledge of the fraudulent activities in its Chinese operations. According to the Daily Telegraph, Witty was prepared to admit that a scam had occurred within the Chinese operations.

Chinese authorities found GSK guilty and levied a fine of roughly 3 billion yuan, around £300 million. The scandal forced GSK to overhaul its sales and marketing practices worldwide. They stopped paying doctors to promote drugs and decoupled sales rep pay from the number of GSK prescriptions written.

Departure from GSK

In March 2016, the BBC reported that Witty would leave as GSK's CEO in 2017, after nearly a decade leading the company. Emma Walmsley took over as his successor, becoming the first woman to lead a major pharmaceutical company. His tenure had balanced two big priorities. He expanded healthcare access in developing countries while reshaping GSK's product portfolio, including buying Novartis's vaccines business and selling its oncology assets to Novartis.

UnitedHealth Group (2018–2025)

Optum Presidency

UnitedHealth Group appointed Witty as president of its Optum division in March 2018, according to Reuters. This role marked his shift from pharma to American health insurance and services. Optum, UnitedHealth's health services arm, ran pharmacy benefit management, data analytics, and healthcare delivery operations. It was one of the company's fastest-growing pieces, and Witty was tasked with pushing that growth further.

COVID-19 Vaccine Work with the WHO

Witty took temporary leave from Optum in April 2020 during the pandemic to assist the World Health Organization. Forbes reported that he'd help the WHO coordinate global vaccine development for COVID-19. As special envoy, he worked to ensure vaccines reached both developed and developing nations fairly. The appointment made sense given his history with global health. He'd spent years at GSK expanding medicine access in lower-income countries.

CEO of UnitedHealth Group

In February 2021, Witty became chief executive officer of UnitedHealth Group, replacing David Wichmann. UnitedHealth was the largest health insurance company in the United States by revenue, operating its UnitedHealthcare insurance side and the Optum health services segment. Witty pushed the company's integrated model of insurance and healthcare delivery. Optum's physician practices, ambulatory surgery centres, and home health operations expanded substantially under his watch.

Challenges mounted. Regulators, lawmakers, and the public scrutinised UnitedHealth's dual role as both insurer and healthcare provider, which many saw as creating conflicts of interest. The company also faced rising concerns about prior authorisation practices and claim denials across the whole insurance industry.

December 2024 brought tragedy. UnitedHealthcare CEO Brian Thompson was killed in a targeted shooting in New York City, shaking the company and the entire healthcare sector. That incident reignited public debate about health insurance and put intense focus on UnitedHealth Group.

Departure from UnitedHealth Group

On 13 May 2025, UnitedHealth announced Witty was stepping down as CEO immediately, citing "personal reasons." Media outlets widely called the departure abrupt. The company also suspended its 2025 financial outlook at the same time, unsettling investors further.

Stephen Hemsley took his place. He's UnitedHealth's board chairman and a former CEO who returned to the top job on an interim basis. NPR said the leadership shift deepened what was already a terrible stretch for the company, which was dealing with multiple operational, regulatory, and reputational problems.

Pharmaphorum reported that Witty resigned as the company withdrew its financial forecasts, tying the leadership change to broader instability at UnitedHealth.

Seeking Alpha revealed after his exit that Witty's 2024 compensation put him at the top of the pay list among US managed care executives.

Personal Life

Witty is married to Caroline Hall. They have two children. He's kept his personal life fairly private throughout his career.

Beyond his corporate roles, Witty has been connected to several non-profit and academic institutions. His appointment as chancellor of the University of Nottingham reflected his long connection to where he studied. He stepped down from that role in 2017, when he also left GSK.

Singapore's government gave him the Honorary Citizen Award in 2018, recognizing his contributions to the country during his time running GSK's Asia-Pacific operations.

Recognition

Witty received a knighthood in the 2012 New Year Honours for services to the UK economy and the pharmaceutical industry, letting him use the title "Sir." The honour recognised his GSK leadership and his work expanding access to medicines in developing countries.

In 2018, Singapore honoured Witty with the Honorary Citizen Award, one of the country's highest distinctions for foreign nationals. The award acknowledged his significant contributions to Singapore throughout his career, especially through GSK's operations and investments there.

Forbes profiled Witty during his GSK years as one of the notable figures in global pharmaceuticals. His drug pricing initiatives for developing countries got attention from global health organisations and media outlets like The Guardian.

His WHO work during COVID-19 brought more public recognition. People noted his efforts coordinating vaccine development and distribution at a time when the world needed it most.

Legacy

Witty led two of the largest organisations in global healthcare over four decades. GlaxoSmithKline came first, then UnitedHealth Group. His GSK years stood out for introducing policies that expanded medicine access in developing countries, including tiered pricing and patent-sharing for neglected tropical diseases. These approaches departed from how most of the industry operated then and shaped later conversations about pharmaceutical pricing and intellectual property in global health.

The China scandal, though, was a major problem for GSK's reputation while Witty was in charge. It forced the company to overhaul sales and marketing worldwide. The reforms they made, including ending physician payments for promoting products, were later adopted or considered by other pharmaceutical companies.

At UnitedHealth Group, Witty oversaw continued expansion, growing the Optum health services division under his leadership. His May 2025 departure came during intense scrutiny of American health insurance, following Brian Thompson's killing in December 2024 and mounting pressure on insurers from regulators and the public about their business practices.

His temporary WHO role during the COVID-19 pandemic was unusual for a sitting corporate executive. It reflected his long engagement with global health policy, something that'd mattered to him since his early days managing GSK's work in Africa and other developing regions.